201 related articles for article (PubMed ID: 18085475)
21. A critical review on modulators of Multidrug Resistance Protein 1 in cancer cells.
Poku VO; Iram SH
PeerJ; 2022; 10():e12594. PubMed ID: 35036084
[TBL] [Abstract][Full Text] [Related]
22. Altered expression of the MYCN oncogene modulates MRP gene expression and response to cytotoxic drugs in neuroblastoma cells.
Haber M; Bordow SB; Gilbert J; Madafiglio J; Kavallaris M; Marshall GM; Mechetner EB; Fruehauf JP; Tee L; Cohn SL; Salwen H; Schmidt ML; Norris MD
Oncogene; 1999 Apr; 18(17):2777-82. PubMed ID: 10348353
[TBL] [Abstract][Full Text] [Related]
23. MYCN silencing induces differentiation and apoptosis in human neuroblastoma cells.
Kang JH; Rychahou PG; Ishola TA; Qiao J; Evers BM; Chung DH
Biochem Biophys Res Commun; 2006 Dec; 351(1):192-7. PubMed ID: 17055458
[TBL] [Abstract][Full Text] [Related]
24. Targeted MYCN expression affects cytotoxic potential of chemotherapeutic drugs in neuroblastoma cells.
Paffhausen T; Schwab M; Westermann F
Cancer Lett; 2007 May; 250(1):17-24. PubMed ID: 17141950
[TBL] [Abstract][Full Text] [Related]
25. Multidrug resistance-associated protein 1 (MRP1) expression in neuroblastoma cell lines and primary tumors.
Goto H; Keshelava N; Matthay KK; Lukens JN; Gerbing RB; Stram DO; Seeger RC; Reynolds CP
Med Pediatr Oncol; 2000 Dec; 35(6):619-22. PubMed ID: 11107131
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule multidrug resistance-associated protein 1 inhibitor reversan increases the therapeutic index of chemotherapy in mouse models of neuroblastoma.
Burkhart CA; Watt F; Murray J; Pajic M; Prokvolit A; Xue C; Flemming C; Smith J; Purmal A; Isachenko N; Komarov PG; Gurova KV; Sartorelli AC; Marshall GM; Norris MD; Gudkov AV; Haber M
Cancer Res; 2009 Aug; 69(16):6573-80. PubMed ID: 19654298
[TBL] [Abstract][Full Text] [Related]
27. Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus.
Binyamin L; Assaraf YG; Reiter Y
Int J Cancer; 2005 Sep; 116(5):703-9. PubMed ID: 15838832
[TBL] [Abstract][Full Text] [Related]
28. Redox regulation of multidrug resistance in cancer chemotherapy: molecular mechanisms and therapeutic opportunities.
Kuo MT
Antioxid Redox Signal; 2009 Jan; 11(1):99-133. PubMed ID: 18699730
[TBL] [Abstract][Full Text] [Related]
29. Oncogene MYCN regulates localization of NKT cells to the site of disease in neuroblastoma.
Song L; Ara T; Wu HW; Woo CW; Reynolds CP; Seeger RC; DeClerck YA; Thiele CJ; Sposto R; Metelitsa LS
J Clin Invest; 2007 Sep; 117(9):2702-12. PubMed ID: 17710228
[TBL] [Abstract][Full Text] [Related]
30. ID2 expression in neuroblastoma does not correlate to MYCN levels and lacks prognostic value.
Vandesompele J; Edsjö A; De Preter K; Axelson H; Speleman F; Påhlman S
Oncogene; 2003 Jan; 22(3):456-60. PubMed ID: 12545167
[TBL] [Abstract][Full Text] [Related]
31. The coamplification pattern of the MYCN amplicon is an invariable attribute of most MYCN-amplified human neuroblastomas.
Weber A; Starke S; Bergmann E; Christiansen H
Clin Cancer Res; 2006 Dec; 12(24):7316-21. PubMed ID: 17189403
[TBL] [Abstract][Full Text] [Related]
32. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro.
Norris MD; Smith J; Tanabe K; Tobin P; Flemming C; Scheffer GL; Wielinga P; Cohn SL; London WB; Marshall GM; Allen JD; Haber M
Mol Cancer Ther; 2005 Apr; 4(4):547-53. PubMed ID: 15827327
[TBL] [Abstract][Full Text] [Related]
33. Amplified MYCN in human neuroblastoma: paradigm for the translation of molecular genetics to clinical oncology.
Schwab M
Ann N Y Acad Sci; 2002 Jun; 963():63-73. PubMed ID: 12095930
[TBL] [Abstract][Full Text] [Related]
34. New insights into the mechanisms of gastric cancer multidrug resistance and future perspectives.
Zhang D; Fan D
Future Oncol; 2010 Apr; 6(4):527-37. PubMed ID: 20373867
[TBL] [Abstract][Full Text] [Related]
35. Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma.
Gupta A; Williams BR; Hanash SM; Rawwas J
Cancer Res; 2006 Aug; 66(16):8100-8. PubMed ID: 16912187
[TBL] [Abstract][Full Text] [Related]
36. How does MYCN amplification make neuroblastomas behave aggressively? Still more questions than answers.
Maris JM
Pediatr Blood Cancer; 2005 Dec; 45(7):869-70. PubMed ID: 16206200
[No Abstract] [Full Text] [Related]
37. Rapamycin inhibits proliferation of human neuroblastoma cells without suppression of MycN.
Misawa A; Hosoi H; Tsuchiya K; Sugimoto T
Int J Cancer; 2003 Mar; 104(2):233-7. PubMed ID: 12569580
[TBL] [Abstract][Full Text] [Related]
38. Multidrug resistance-associated protein 1 (MRP1/ABCC1) polymorphism: from discovery to clinical application.
Yin J; Zhang J
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2011 Oct; 36(10):927-38. PubMed ID: 22086004
[TBL] [Abstract][Full Text] [Related]
39. MYCN-directed centrosome amplification requires MDM2-mediated suppression of p53 activity in neuroblastoma cells.
Slack AD; Chen Z; Ludwig AD; Hicks J; Shohet JM
Cancer Res; 2007 Mar; 67(6):2448-55. PubMed ID: 17363562
[TBL] [Abstract][Full Text] [Related]
40. [Multidrug resistance-associated proteins and their roles in multidrug resistance].
Zhang H; Fu LW
Yao Xue Xue Bao; 2011 May; 46(5):479-86. PubMed ID: 21800532
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
